SCHEMBL3016509

SCHEMBL3016509

COc1ccc(S(=O)(=O)N2CCN(c3nc(-c4ccc(F)c(F)c4)cs3)CC2)c(OC)c1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.60
HSD17B10 Q99714 2/20 0.60
USP2 O75604 1/20 0.60
RECQL P46063 1/20 0.60
SMN1; SMN2 Q16637 6/20 0.51
ALDH1A1 P00352 5/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
POLB P06746 2/20 0.51
LMNA P02545 6/20 0.50
TDP1 Q9NUW8 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
MAPK1 P28482 5/20 0.49
TP53 P04637 3/20 0.48
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
HTT P42858 3/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007778 0.93 MAPT (0.58) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3011924 0.93 MAPT (0.58) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3006380 0.93 MAPT (0.60) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3014348 0.91 POLB (0.59) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3007685 0.90 MAPT (0.59) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3007441 0.89 MAPT (0.54) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3016261 0.89 MAPT (0.61) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3646268 0.89 MAPT (0.54) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3013335 0.88 MAPT (0.56) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3007488 0.88 MAPT (0.56) MAPTHSD17B10USP2RECQLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HSD17B10 2553/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.